Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences, Inc. is positioned for substantial growth, with lead product Ingrezza projected to achieve approximately $3 billion in sales by 2028, driven by double-digit prescription growth despite net price pressures. The company's expanding pipeline, boasting the potential to introduce one new medicine every two years and two Phase 3 trials currently underway, strengthens the outlook for long-term revenue earnings. Additionally, early traction for Crenessity in the classical CAH market, with expectations of peak revenues exceeding $1 billion by 2030, further underscores the firm’s promising financial trajectory.

Neurocrine Biosciences Inc. experienced a significant earnings miss in the fourth quarter of 2025, reporting a non-GAAP EPS of $1.88 compared to consensus expectations of $2.31, which raises concerns about the company's profitability. The downward revision of revenue estimates for FY26, particularly for Ingrezza, reflects an anticipated 5% decline in net pricing, contributing to a revenue estimate adjustment down to approximately $2,729 million. Additionally, competition risks and increased research and development expenses, particularly in Phase 3 studies, are likely to hinder Neurocrine's financial performance, overshadowing potential growth initiatives and leading to a downward adjustment in its price target.